Blog
RSS FeedPosted by Michael Wonder on 08 Jun 2020
Fate of pharma’s reputation lies in Gilead’s hands on pricing of COVID-19 drug remdesivir
8 June 2020 - Few remember the time when the pharmaceutical industry was the world’s most admired. ...
Posted by Michael Wonder on 03 Jun 2020
Paying for value from costly medical technologies: a framework for applying value-based payment reforms
2 June 2020 - Innovative medical products offer significant and potentially transformative impacts on health, but they create concerns about rising ...
Posted by Michael Wonder on 02 Jun 2020
Traditional cost effectiveness formulas and precision medicines
1 June 2020 - Cost effectiveness analyses, which are often conducted to evaluate new medicines, use a standardised framework to ...
Posted by Michael Wonder on 26 May 2020
ICER releases draft evidence report on ulcerative colitis therapies
26 May 2020 - Public comment period now open until 29 July 2020; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 21 May 2020
ISPOR holds its first completely virtual conference
21 May 2020 - Virtual ISPOR 2020 plenaries focused on health policy, big data and artificial intelligence, cost effectiveness analysis and ...
Posted by Michael Wonder on 20 May 2020
Valuing and pricing remdesivir: should drug makers get paid for helping us get back to work?
20 May 2020 - On April 29, the National Institutes of Health announced that in a placebo-controlled trial of patients with ...
Posted by Michael Wonder on 20 May 2020
ICER posts draft scoping document for the assessment of supervised injection facilities
19 May 2020 - Document open to public comment until 9 June 2020. ...
Posted by Michael Wonder on 18 May 2020
International reference pricing gets thumbs down from ISPOR panel
18 May 2020 - International reference pricing, by which drug prices would be pegged to international standards, is under consideration ...
Posted by Michael Wonder on 15 May 2020
Putting a dollar value on life? Governments already do
11 May 2020 - Trade-offs are routine in health policy, and the math and analysis underlying them have been around for ...
Posted by Michael Wonder on 14 May 2020
ICER appoints new members to each of its three independent evidence appraisal councils
14 May 2020 - New members bring expertise in broad range of perspectives, including patient advocacy, health policy, economics, and clinical ...
Posted by Michael Wonder on 14 May 2020
ICER’s cost model is not only wrong it’s also dangerous
11 May 2020 - There they go again. ...
Posted by Michael Wonder on 07 May 2020
How are incremental cost effectiveness, contextual considerations, and other benefits viewed in health technology assessment recommendations in the United States?
7 May 2020 - This study reviews ICER assessments to explore the relationship between incremental cost-effectiveness, other benefits, and contextual factors ...
Posted by Michael Wonder on 01 May 2020
ICER presents alternative pricing models for remdesivir as a treatment for COVID-19
1 May 2020 - Models present prices according to two different paradigms: “cost recovery” approach and traditional cost-effectiveness analysis. ...
Posted by Michael Wonder on 01 May 2020
The global imperative to make cancer medications affordable
1 May 2020 - The value of any medication is determined by the magnitude of the clinical benefit (improved survival and ...
Posted by Michael Wonder on 30 Apr 2020
Using QALYs versus DALYs to measure cost effectiveness: how much does it matter?
30 April 2020 - Quality-adjusted life-years and disability-adjusted life-years are commonly used in cost effectiveness analysis to measure health benefits. Gent ...